Related Experiment Video
Updated: Jan 28, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity
Jianwen Pei1, Yibo Zhang1, Qinhong Luo1
1State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.
Abstract:
Cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is a key regulator in innate immunity and has emerged as a promising drug target in cancer treatment, but the utility of this pathway in therapeutic development is complicated by its dichotomous roles in tumor development and immunity. The activation of the STING pathway and the induced antitumor immunity could be attenuated by the feedback activation of IL-6/STAT3 pathway. Here we reported that STAT3 inhibition significantly enhanced the intensity and duration of STING signaling induced by the STING agonist c-diAM(PS)2. Such sensitization effect of STAT3 inhibition on STING signaling depended on STING rather than cGAS, which was mediated by simultaneously upregulating the positive modulators and downregulating the negative modulators of the STING pathway. Furthermore, the combination treatment with the STAT3 inhibitor and STING agonist markedly regressed tumor growth in syngeneic mice by increasing CD8+ T cells and reducing regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. Our work provides a rationale for the combination of STAT3 inhibitors and STING agonists in cancer immunotherapy.
Insights
STAT3 inhibition enhances the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway signaling. This combination therapy promotes antitumor immunity by modulating immune cells in the tumor microenvironment.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is crucial for innate immunity and cancer treatment.
- Its therapeutic utility is complex due to dual roles in tumor development and immunity.
- Interleukin-6/STAT3 (Signal Transducer and Activator of Transcription 3) pathway activation can dampen STING-induced antitumor responses.
Purpose of the Study:
- To investigate the effect of STAT3 inhibition on STING pathway activation.
- To explore the therapeutic potential of combining STAT3 inhibitors with STING agonists in cancer immunotherapy.
Main Methods:
- Utilized a STING agonist (c-diAM(PS)2) and a STAT3 inhibitor.
- Assessed STING signaling intensity and duration.
- Analyzed immune cell populations (CD8+ T cells, Tregs, MDSCs) in the tumor microenvironment of syngeneic mouse models.
Main Results:
- STAT3 inhibition significantly amplified STING signaling, dependent on STING rather than cGAS.
- This sensitization involved upregulating positive and downregulating negative modulators of the STING pathway.
- Combination treatment markedly regressed tumor growth by enhancing CD8+ T cells and reducing Tregs and MDSCs.
Conclusions:
- STAT3 inhibition potentiates STING pathway signaling and antitumor immunity.
- Combining STAT3 inhibitors with STING agonists offers a promising strategy for cancer immunotherapy.
Related Concept Videos
What is the Immune System?
Feedback Inhibition
Humoral Immune Responses
Bacterial Signaling
Enzyme Inhibition
What is Cell Signaling?

